NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks at the Global Passion Project and Rockefeller Capital symposium held Aug. 28–30, 2025, in Southampton, N.Y. CEO Prof. Jonathan Javitt, MD, MPH, outlined plans for the Fall 2025 launch of HOPE Therapeutics clinics and a one-week residential program targeting suicidal depression, PTSD, traumatic brain injury and cognitive dysfunction. The program will be the first in the U.S. to combine neuroplastic drugs such as ketamine with transcranial magnetic stimulation, hyperbaric oxygen therapy, nutritional therapy, outdoor activities and supportive therapy in a comprehensive setting. At the event, Matthew Rockefeller was named to the advisory board of HOPE Therapeutics. The company noted it recently raised more than $8.8 million from biotechnology investors in a common stock offering without warrants or repricing features.
To view the full press release, visit https://ibn.fm/xOovx
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
